CQUEST responds to the FDA's draft guidance on core PROs in cancer trials

The CQUEST team, along with Jessica Roydhouse1 of the Menzies Institute for Medical Research, University of Tasmania, recently wrote an editorial in response to implementing the FDA's 2021 draft guidance on core patient-reported outcomes (PROs) in cancer trials. This was published in ISOQOL's QualityTALK newsletter in August 2023. 

Read here: Implementing the FDA's draft guidance on core PROs in cancer trials: the challenge or a modular approach.

1 ISOQOL representative on the CQUEST Steering Committee

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.